ASTERION RESEARCH & DEVELOPMENT
ActiveSummary
ASTERION RESEARCH & DEVELOPMENT has been active since 2017 and the Belgian Official Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €1.6m and a net result of -€621,245. Equity is growing by about 23% per year across the filed financial years. Its solvency ranks better than 70% of 271 sector peers (NACE 72, financial year 2025). The computed 12-month bankruptcy probability is 0.6% (low).
Group and network
Holdings and subsidiaries
2 holdingsHoldings 2
Source for every holding own accounts 2025
- SwiftpharmasubsidiaryEquity €834,755Result -€1.8m52.8%
- Bombi BiomicsNL30%
According to the 2025 annual accounts of ASTERION RESEARCH & DEVELOPMENT and those of the other companies, the acts in the Belgian Official Gazette and the LEI register. Annual accounts state the shareholders that notified the company under article 7:225 of the Code of Companies and Associations and the parent companies that consolidate it. The register of ultimate beneficial owners (UBO) is not public: who ultimately stands behind a natural person or a foreign parent is not stated here. A company that does not include these statements in its annual accounts, or does not have to, is not listed.
Connections & network
The network starts from this company’s shareholders. What else they own or run appears here as nodes.